



## News Release

### **Puma Biotechnology to Present at Cowen's Annual Health Care Conference**

**LOS ANGELES, Calif., March 5, 2019** – Puma Biotechnology, Inc. (NASDAQ: PBYI), a biopharmaceutical company, announced that Alan H. Auerbach, Chairman, Chief Executive Officer, President and Founder of Puma, will provide an overview of the Company at 10:00 a.m. EDT on Tuesday, March 12 at the Cowen and Company 39th Annual Health Care Conference. The conference will be held at the Boston Marriott Copley Place.

A live webcast of the presentation will be available on the Company's website at [www.pumabiotechnology.com](http://www.pumabiotechnology.com). The presentation will be archived on the website and available for 30 days.

#### **About Puma Biotechnology**

Puma Biotechnology, Inc. is a biopharmaceutical company with a focus on the development and commercialization of innovative products to enhance cancer care. The Company in-licenses the global development and commercialization rights to three drug candidates — PB272 (neratinib, oral), PB272 (neratinib, intravenous) and PB357. Neratinib, oral was approved by the U.S. Food and Drug Administration in July 2017 for the extended adjuvant treatment of adult patients with early stage HER2-overexpressed/amplified breast cancer, following adjuvant trastuzumab-based therapy, and is marketed in the United States as NERLYNX® (neratinib) tablets. NERLYNX was granted marketing authorization by the European Commission for the extended adjuvant treatment of hormone receptor-positive HER2-positive early stage breast cancer in September 2018. NERLYNX is a registered trademark of Puma Biotechnology, Inc.

Further information about Puma Biotechnology may be found at [www.pumabiotechnology.com](http://www.pumabiotechnology.com).

#### **Contacts:**

Alan H. Auerbach or Mariann Ohanesian, Puma Biotechnology, Inc., +1 424 248 6500

[info@pumabiotechnology.com](mailto:info@pumabiotechnology.com)

[ir@pumabiotechnology.com](mailto:ir@pumabiotechnology.com)

David Schull or Alex Fudukidis, Russo Partners, +1 212 845 4200

[david.schull@russopartnersllc.com](mailto:david.schull@russopartnersllc.com)

[alex.fudukidis@russopartnersllc.com](mailto:alex.fudukidis@russopartnersllc.com)

#####